About Us

Board of Directors

Vince Owens
Executive Chairman
Functional Neuromodulation, Ltd.

Mr. Owens has 25 years of medical device industry experience, including 12 years as CEO of implantable neuromodulation device startups. Prior to joining Functional Neuromodulation as a director in 2012, he was Co-Founder and CEO of Intelect Medical, a developer of neuromodulation technologies including Guide DBS and directional DBS leads. Mr. Owens led Intelect from startup in 2005 through acquisition by Boston Scientific in 2011. Prior to Intelect, Mr. Owens was CEO of Biomec Cardiovascular, a contract developer of neuromodulation and CRM leads, through acquisition by Enpath Medical (Greatbatch). Mr. Owens serves on the boards of several early stage medical device companies as well as having previously served on technology commercialization boards at Cornell University and Case Western Reserve University. Mr. Owens received his B.S. in Mechanical Engineering from Carnegie Mellon University and his MBA from Ashland University.

Mr. Kelly Holman
Co-Founder and Chairman
Genesys Capital

Mr. Holman is co-Founder and Managing Director of Genesys Capital. Since co-founding the firm in 2000, Mr. Holman has been actively involved in raising over $225 million of venture capital and has been instrumental in deploying over $130 million across 27 investments. He currently serves on the Board of Directors of Epocal, Functional Neuromodulation and InVitae (observer). Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen's University.

Andrew D. Firlik, MD
Co-Founder and General Partner,
Jazz Venture Partners

Previously, Dr. Firlik was General Partner at Foundation Medical Partners concentrating on medical device and healthcare information technology investments. Prior to joining FMP, Dr. Firlik was a venture partner at Sprout Group and Managing Director of its healthcare technology spinout, New Leaf Venture Partners. Dr. Firlik has served as a founder, founding investor, or director of many early stage companies that have grown to become successful market leaders, including Northstar Neuroscience, Inc., NeuroVista Corp. and Intelect Medical, a neuromodulation company acquired by Boston Scientific in January 2011. He studied biology at Cornell University and Oxford University, received his MBA from the University of Pittsburgh, and his MD from Cornell University Medical College.

Andres Lozano, MD, PhD
Director, Founding Scientist, Chairman of SAB
Functional Neuromodulation Ltd.

Dr. Lozano is the Professor and Chairman of the Division of Neurosurgery, and R.R. Tasker Chair in Stereotactic and Functional Neurosurgery of the University Health Network and the University of Toronto. Dr. Lozano originated the concept of treating memory disorders using DBS and co-founded Functional Neuromodulation after successful completion of a pilot study of DBS in six Alzheimer's patients. See Management Bios

Board Observer

Matt Gunderman
VP, Business Development, Strategy, and New Therapies,
Boston Scientific

Matt has been with Boston Scientific since 2003. Prior to his current role Matt held the positions of Director, Business Development and Director, Health Economics & Reimbursement for Boston Scientific Neuromodulation. Previously, Matt spent seven years working in HE&R at Boston Scientifics’ Cardiac Rhythm Management division. Prior to joining Boston Scientific, Matt held a variety of economic, engineering, and consulting positions in several different industries. Matt earned his MBA from the University of Minnesota and a BS in Mechanical Engineering from Iowa State University.

CAUTION — Investigational device. Limited by Federal law to investigational use.